Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Down 18.6% in November

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the recipient of a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 57,000 shares, a decrease of 18.6% from the October 31st total of 70,000 shares. Based on an average trading volume of 36,200 shares, the days-to-cover ratio is currently 1.6 days. Currently, 0.9% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, LADENBURG THALM/SH SH increased their price objective on shares of Marker Therapeutics from $11.00 to $19.00 and gave the company a “buy” rating in a research report on Monday, October 21st.

Hedge Funds Weigh In On Marker Therapeutics

A hedge fund recently raised its stake in Marker Therapeutics stock. Wedbush Securities Inc. raised its holdings in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) by 52.7% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 69,500 shares of the company’s stock after buying an additional 24,000 shares during the quarter. Wedbush Securities Inc. owned about 0.78% of Marker Therapeutics worth $377,000 as of its most recent SEC filing. 22.39% of the stock is owned by hedge funds and other institutional investors.

Marker Therapeutics Trading Up 9.7 %

Shares of MRKR traded up $0.31 during midday trading on Friday, hitting $3.50. The stock had a trading volume of 19,822 shares, compared to its average volume of 25,818. The stock’s 50 day moving average is $3.35 and its 200 day moving average is $3.85. Marker Therapeutics has a 1 year low of $2.44 and a 1 year high of $6.16.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.